Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation.

OBJECTIVES Invasive fungal disease (IFD) remains a major concern in patients with haematological conditions. We describe diagnoses, therapeutic management and outcomes in unselected consecutive patients from haematological facilities treated for suspected or documented IFD. METHODS In this observational prospective study, children/adults with haematological conditions or haematopoietic stem cell transplantation (HSCT) were recruited upon start of non-prophylactic systemic antifungal treatment in 37 French haematological facilities (December 2007 to December 2008). IFD episodes were classified according to the 2008 EORTC/MSG criteria. RESULTS The cohort included 419 patients (298 adults and 121 children): 88% haematological malignancies, 28% HSCT recipients and 68% neutropenic. Patients had 423 IFD episodes: 21% mycologically documented (59% probable/proven aspergillosis, 32% proven candidiasis and 9% probable/proven other IFD) and 20% classified as possible IFD. The remaining cases were assigned to two groups: febrile neutropenia (34%) and unclassified (25%), 9% of which were classified as possible/probable/proven IFD by day 7. Treatment was thus initiated early in 59% of patients; liposomal amphotericin B and caspofungin were the most common single-agent therapies. The 12 week mortality was 18% for probable/proven aspergillosis, 15% for proven candidiasis, 10% for probable/proven other IFD, 9% for possible IFD, 3% for febrile neutropenia and 12% for unclassified episodes (log rank P = 0.016); it was dependent on age, complete remission of underlying haematological disease and mechanical ventilation. CONCLUSIONS In this comprehensive sample of haematological patients receiving antifungal treatment, we observe a widespread resort to early therapy and a low mortality rate, including in patients with probable or proven IFD.

[1]  B. Lebeau,et al.  Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  R. Ebrahimi,et al.  Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease , 2011, Mycoses.

[3]  A. Localio,et al.  Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Giuseppe Leone,et al.  Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study , 2010, Haematologica.

[5]  A. Vekhoff,et al.  Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Philippe Lutun,et al.  Factors associated with overall and attributable mortality in invasive aspergillosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  L. Leibovici,et al.  Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis. , 2008, European journal of cancer.

[9]  J. Perfect,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  K. Marr,et al.  Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients , 2007, British journal of haematology.

[12]  T. Calandra,et al.  Empirical antifungal therapy in neutropaenic cancer patients with persistent fever , 2007 .

[13]  C. Heussel,et al.  Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Boeckh,et al.  Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  L. Bevanger,et al.  Candidemia in Norway (1991 to 2003): Results from a Nationwide Study , 2006, Journal of Clinical Microbiology.

[16]  B. D. de Pauw,et al.  Should the consensus guidelines' specific criteria for the diagnosis of invasive fungal infection be changed? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Richardson,et al.  Changing patterns and trends in systemic fungal infections. , 2005, The Journal of antimicrobial chemotherapy.

[18]  Victoria J. Fraser,et al.  Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality , 2005, Antimicrobial Agents and Chemotherapy.

[19]  O. Lortholary,et al.  A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999. , 2004, The Journal of antimicrobial chemotherapy.

[20]  M. Boeckh,et al.  Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. , 2002, Blood.

[21]  Lawrence Corey,et al.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  L. Pagano,et al.  Design and Methods , 2022 .